- Home
- CANF vs LDWY Comparison
CANF vs LDWY Comparison
Compare CANF & LDWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- LDWY
- Stock Information
- Founded
- CANF 1994
- LDWY 1990
- Country
- CANF Israel
- LDWY United States
- Employees
- CANF N/A
- LDWY N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- LDWY Advertising
- Sector
- CANF Health Care
- LDWY Consumer Discretionary
- Exchange
- CANF Nasdaq
- LDWY Nasdaq
- Market Cap
- CANF 9.6M
- LDWY 8.9M
- IPO Year
- CANF N/A
- LDWY 1991
- Fundamental
- Price
- CANF $0.50
- LDWY $4.63
- Analyst Decision
- CANF Strong Buy
- LDWY
- Analyst Count
- CANF 2
- LDWY 0
- Target Price
- CANF $14.50
- LDWY N/A
- AVG Volume (30 Days)
- CANF 280.9K
- LDWY 1.5K
- Earning Date
- CANF 11-27-2025
- LDWY 11-18-2025
- Dividend Yield
- CANF N/A
- LDWY N/A
- EPS Growth
- CANF N/A
- LDWY N/A
- EPS
- CANF N/A
- LDWY 1.66
- Revenue
- CANF $560,000.00
- LDWY $71,244,000.00
- Revenue This Year
- CANF $461.72
- LDWY N/A
- Revenue Next Year
- CANF N/A
- LDWY N/A
- P/E Ratio
- CANF N/A
- LDWY $3.01
- Revenue Growth
- CANF N/A
- LDWY 187.12
- 52 Week Low
- CANF $0.47
- LDWY $3.12
- 52 Week High
- CANF $3.02
- LDWY $6.19
- Technical
- Relative Strength Index (RSI)
- CANF 31.15
- LDWY 38.38
- Support Level
- CANF $0.49
- LDWY $4.69
- Resistance Level
- CANF $0.55
- LDWY $5.04
- Average True Range (ATR)
- CANF 0.03
- LDWY 0.22
- MACD
- CANF -0.00
- LDWY -0.04
- Stochastic Oscillator
- CANF 13.94
- LDWY 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.